Jacquline Msefula
Overview
Explore the profile of Jacquline Msefula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hackman J, Hibberd M, Swarthout T, Hinds J, Ashall J, Sheppard C, et al.
Microbiol Spectr
. 2024 Nov;
:e0364323.
PMID: 39499074
Detection of multiple pneumococcal serotype carriage can enhance monitoring of pneumococcal vaccine impact, particularly among high-burden childhood populations. We assessed methods for identifying co-carriage of pneumococcal serotypes from whole-genome sequences....
2.
Kalizangoma A, Swarthout T, Mwalukomo T, Kamngona A, Brown C, Msefula J, et al.
J Infect Dis
. 2024 Jul;
230(1):e189-e198.
PMID: 39052729
Background: Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We...
3.
Cave R, Kalizangoma A, Chaguza C, Mwalukomo T, Kamngona A, Brown C, et al.
Microb Genom
. 2024 Jun;
10(6).
PMID: 38896467
Since the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Malawi in 2011, there has been persistent carriage of vaccine serotype (VT) , despite high vaccine coverage. To determine...
4.
5.
Obolski U, Swarthout T, Kalizangoma A, Mwalukomo T, Chan J, Weight C, et al.
Nat Commun
. 2023 Nov;
14(1):7477.
PMID: 37978177
Streptococcus pneumoniae causes substantial mortality among children under 5-years-old worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing vaccine serotype disease, but emergence of non-vaccine serotypes and persistent nasopharyngeal...
6.
Kirolos A, Swarthout T, Mataya A, Bonomali F, Brown C, Msefula J, et al.
BMC Infect Dis
. 2023 Jan;
23(1):56.
PMID: 36703117
Introduction: The introduction of PCV13 to the Malawi infant immunization schedule in 2011 has been associated with reduced disease from Streptococcus pneumoniae. Improved understanding of serotypes with high invasive potential...
7.
Wolf A, Mitsi E, Jones S, Jochems S, Roalfe L, Thindwa D, et al.
Vaccine
. 2022 Oct;
40(50):7201-7210.
PMID: 36210249
Childhood pneumococcal conjugate vaccine (PCV) protects against invasive pneumococcal disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating opsonophagocytic anti-capsular antibodies, but how vaccination protects against and reduces VT carriage...
8.
Swarthout T, Henrion M, Thindwa D, Meiring J, Mbewe M, Kalizangoma A, et al.
Lancet Infect Dis
. 2022 Aug;
22(12):1737-1747.
PMID: 36029796
Background: Pneumococcal conjugate vaccines (PCVs) induce serotype-specific IgG antibodies, effectively reducing vaccine-serotype carriage and invasive pneumococcal disease (IPD). IgG production wanes approximately 1 month after vaccination in absence of serotype-specific...
9.
Thindwa D, Mwalukomo T, Msefula J, Jambo K, Brown C, Kamngona A, et al.
AIDS
. 2022 Aug;
36(14):2045-2055.
PMID: 35983828
Objective: Adults living with HIV (ALWHIV) on antiretroviral therapy (ART) are at high risk of pneumococcal carriage and disease. To help evaluate carriage risk in African ALWHIV at least 4...
10.
Koenraads M, Swarthout T, Bar-Zeev N, Brown C, Msefula J, Denis B, et al.
Pediatr Infect Dis J
. 2022 Jun;
41(9):764-768.
PMID: 35703302
Background: Invasive pneumococcal disease (IPD) in young infants is uncommon but associated with high morbidity and mortality. Accurate data on the burden of IPD in young infants in low-income countries...